Fate Therap

Q2 FY2026 EarningsQ2 FY26 results beat consensus across key metrics, with revenue of $2.1M exceeding the $1.3M expected and a narrower GAAP net loss of $(0.25) per share vs. the $(0.27) anticipated. The top-line beat was driven by preclinical collaboration activities with Ono Pharmaceutical, while total operating expenses decreased by $14.3M YoY due to strategic cost discipline. With $153.8M in cash and a runway extended into 2028, the company is well-capitalized to advance its lead candidate FT819 into a potentially registrational Phase 2 trial for lupus nephritis.